|
| Issue Date | Title | Author(s) |
| 2022 | A Critical Review of Chloroquine and Hydroxychloroquine as Potential Adjuvant Agents for Treating People with Cancer | Abdel-Aziz, Amal Kamal ; Saadeldin, Mona Kamal; Salem, Ahmed Hamed; Ibrahim, Safaa A.; Shouman, Samia; Abdel-Naim, Ashraf B.; Orecchia, Roberto |
| 2024 | Deciphering the Complex Interplay of Long Noncoding RNAs and Aurora Kinases: Novel Insights into Breast Cancer Development and Therapeutic Strategies | Saadeldin, Mona Kamal; Curigliano, Giuseppe; Abdel-Aziz, Amal Kamal |
| Jan-2021 | Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis | Saadeldin, Mona Kamal; Abdel-Aziz, Amal Kamal ; Abdellatif, Ahmed |
| Nov-2023 | FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review | Abdel-Aziz, Amal Kamal ; Dokla, Eman M E; Saadeldin, Mona Kamal |
| 1-Dec-2021 | Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer | Dokla, Eman ; Abdel-Aziz, Amal Kamal ; Milik, Sandra N.; Mahmoud, Amr H.; Saadeldin, Mona Kamal; McPhillie, Martin J.; Minucci, Saverio; Khaled A M Abouzid |
| 2019 | Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside | Abdel-Aziz, Amal Kamal ; Saadeldin, Mona Kamal; D'Amico, Paolo; Orecchioni, Stefania; Bertolini, Francesco; Curigliano, Giuseppe; Minucci, Saverio |
| 2018 | Serum sclerostin and irisin as predictive markers for atherosclerosis in Egyptian type II diabetic female patients: A case control study | Saadeldin, Mona Kamal; Elshaer, Shereen Saeid; Emara, Ibrahim Ali; Maged, Mohamad; Abdel-Aziz, Amal Kamal |
| 2020 | Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition | Abdel-Aziz, Amal Kamal ; Pallavicini, Isabella; Ceccacci, Elena; Meroni, Giuseppe; Saadeldin, Mona Kamal; Varasi, Mario; Minucci, Saverio |
